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Observational studies suggest that low 25-hydroxyvitamin D status is common and has
been associated with higher mortality in critically ill patients. This study aim to investigate
whether vitamin D supplementation is associated with lower mortality in critically ill patients.
Method
We searched Medline, Embase, and Cochrane databases from inception to January 12,
2020, without language restrictions, for randomized controlled trials comparing the effect of
vitamin D supplementation with placebo in critically ill patients. Two authors independently
performed data extraction and assessed study quality. The primary outcome was all-cause
mortality at the longest follow-up.
Result
We identified nine trials with a total of 2066 patients. Vitamin D supplementation was not
associated with reduced all-cause mortality at the longest follow-up (RR 0.90, 95% CI 0.74
to 1.09, I2 = 20%), at 30 days (RR 0.81, 95% CI 0.56 to 1.15), at 90 days (RR 1.15, 95% CI
0.92 to 1.44), and at 180 days (RR 0.82, 95% CI 0.65 to 1.03). Results were similar in the
sensitivity analysis. The sample size met the optimum size in trial sequential analysis. Simi-
larly, supplemental vitamin D was not associated with length of ICU stay, hospital stay, or
mechanical ventilation.
Conclusion
Vitamin D supplement was not associated with reduced all-cause mortality in critically ill
patients.
PLOS ONE
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Background
Vitamin D plays an important role in maintaining the normal function of neurologic, cardio-
vascular, respiratory, and immune system [1, 2]. Observational studies have indicated that
vitamin D deficiency is common in critically ill patients and is associated with mortality and
length of ICU stay [3, 4]. Early randomized clinical trials (RCTs) individual showed lower
observed mortality than placebo, although the differences were not significant [5–10]. In 2017
and 2018, three systematic reviews [11–13] have discussed the association between vitamin D
supplementation and the most important clinical outcomes: all-cause mortality. One review
[12] has shown benefit of vitamin D on survival, while two reviews [11, 13] have not shown
the benefit. The ongoing debate has been fueled by the recent publications, two large RCTs [5,
14]. Thus, we performed a systematic review and meta-analysis to assess the effect of vitamin
D compared to placebo on mortality.
Method
Protocol and guidance
This systematic review and meta-analysis has been reported in accordance with the preferred
reporting items for systematic reviews and meta-analyses (PRISMA) statement (eTable 1 in S1
Appendix) [15]. We registered a protocol for the review in Open Science Framework https://
osf.io/bgsjq.
Eligibility criteria
Eligible studies met the following PICOS (participants, interventions, comparators, outcomes,
and study design) criteria: (1) Population: adults admitted to the intensive care unit. (2) Inter-
vention: administration of vitamin D, without restrictions in the type, dose, duration, or route
of administration. (3) Comparison: placebo or no treatment. (4) Outcome: The primary out-
come was all-cause mortality at the longest follow-up; second outcomes included mortality at
30 days, mortality at 90 days, mortality at 180 days, ICU mortality, in-hospital mortality, length
of hospital stay, length of ICU stay, and length of mechanical ventilation. (5) Study design:
RCT.
Search strategy
We did computerized literature searches of Medline, Embase, and Cochrane CENTRAL Regis-
ter of Controlled Trials from inception through January 12, 2020, without any language
restrictions. The reference lists of included studies and reviews were searched for additional
studies. Finally, we searched the World Health Organization’s International Clinical Trials
Registry Platform to identify ongoing trials and evaluate the possibility of publication bias. The
details of the search strategy are in eTable 2 in S1 Appendix.
Study selection
After removal of duplicates, two investigators (LP and PW) screen each title and abstract inde-
pendently and in duplicate. The full texts of the remaining studies were also assessed
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independently and in duplicate by the two authors (LP and PW). Discrepancies were resolved
through discussion among the study team.
Data extraction
Two investigators (HD and HF) independently and in duplicate extracted data about study
characteristics, outcomes, and funding sources from the eligible trials using a predesigned
spreadsheet for further analysis. Discrepancies were resolved through discussion among the
study team. Correspondent authors of trials were contacted for unclear information and addi-
tional information that did not report outcomes of interest.
Risk of bias
Risk of bias assessment was conducted by two investigators (LP and PW) using Cochrane Col-
laboration risk of bias tool 2 across seven domains. (https://methods.cochrane.org/bias/news/
rob-2-tool) The individual domains included (1) random-sequence generation, (2) allocation
sequence concealment, (3) blinding of participants and personnel, (4) blinding of outcome
assessment, (5) completeness of outcome data, (6) selective reporting, and (7) other sources of
bias.
Data synthesis
All meta-analyses were conducted using Review Manager version 5.4 (Cochrane Collabora-
tion). We calculated the relative risk (RR) with 95% CI for dichotomous outcomes and the
mean difference with 95% CI for continuous outcomes. I2 values were calculated to estimate
variation among studies attributable to heterogeneity. We calculated pooled effect sizes using
random-effects models regardless of the value of I2 in a meta-analysis. We planned to examine
publication bias via funnel plots (visually) and more formally with the Begg test and Egger test.
Subgroup analysis
We conducted some subgroup analyses to test interactions according to the dose (�300000IU
or<300000IU), baseline 25 hydroxyvitamin D (�20 or <20 ng/ml) and the route of adminis-
tration (oral, intravenous, or intramuscular).
Sensitivity analyses
We conducted sensitivity analyses to test the robustness of the findings included the following:
using fixed-effect models, using absolute risk, and excluding trials at each time.
Trial sequential analysis
We conducted a trial sequential analysis for the primary outcome. An optimal information
size set to an overall 5% risk of type I error, 80% power, and relative risk reduction of 20%.
Trial sequential analysis was done using Trial Sequential Analysis v.0.9.5.10 beta (Copenhagen
Trial Unit, Copenhagen, Denmark).
Quality of evidence
The grading of recommendations assessment, development and evaluation (GRADE) method-
ology was used for assessing the quality of evidence by two investigators (LP and PW) [16].
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Result
Study selection and study characteristics
Our systematic electronic literature search identified a total of 411 reports (Fig 1). After the
exclusion of incomplete reports, nine trials [5–8, 10, 17–20] were included in the systematic
reviews and meta-analyses.
Details of the trials are summarized in Table 1. All studies were published between 2011
and 2020. The number of recipients ranged from 25 to 1078 patients. The route of administra-
tion of vitamin D varied across trials, with six trials [5, 8, 10, 17–19] using oral vitamin D, and
one [20] intravenous, two [6, 7] intramuscular. All trials used placebo as a control.
Fig 1. Search strategy and final included and excluded studies.
https://doi.org/10.1371/journal.pone.0243768.g001
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Risk of bias and quality of evidence
eFigs 1 and 2 in S1 Appendix present risk-of-bias assessments. eTable 6 in S1 Appendix shows
the support for judgment for included trials rated as high or unclear risk of bias. All trials had
a low risk of bias [10, 17, 21–27]. Key findings of GRADE assessment of certainty for all out-
comes are presented in eTable 4 in S1 Appendix. The quality of evidence of primary outcome
was ranked as high.
Mortality
The association between vitamin D and all-cause mortality is shown in Fig 2. The RR revealed
no association between vitamin D and reduced all-cause mortality at the longest follow-up
(RR 0.90; 95% CI, 0.74 to 1.09; I2 = 20%; 26 fewer events per 1000 [95% CI, -69 to 23]; high-
quality evidence).
In trial sequential analyses of all-cause mortality at the longest follow-up, the effect esti-
mated has reached the futility boundary (eFig 3 in S1 Appendix). Sensitivity analyses by
excluding trials at each time and using random-effect models yielded similar results (eTable 5
in S1 Appendix). Funnel plot analysis showed no asymmetry (eFig 4 in S1 Appendix), as well
as Egger test (p = 0.397) and Begg test (p = 0.602) detected no significant small-study effects.
Subgroup analyses found that there is no significant difference between vitamin D supple-
mentation and placebo in the subgroup analysis of all-cause mortality on dose (�300000IU or
<300000IU) (eFig 5 in S1 Appendix), the baseline 25 hydroxyvitamin D (�20 and<20 ng/ml)
(eFig 6 in S1 Appendix) and the route of administration (oral, intravenous, or intramuscular).
Similarly, the use of vitamin D was not associated with reduced all-cause mortality at 30
days, all-cause mortality at 90 days, all-cause mortality at 180 days, all-cause ICU mortality, or
all-cause in-hospital mortality (Fig 2).
Other outcomes
Seven trials [5, 8, 10, 17–20] reported length of hospital stay, and seven trials [5, 6, 8, 10, 17, 19,
20] reported the length of ICU stay. One thousand thirteen patients take vitamin D and 983
Table 1. Characteristics of studies included in the systematic review of vitamin D supplement in critically ill patients.
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patients did not take vitamin D. The mean difference (MD) between the vitamin D group and
placebo group revealed no association between vitamin D and length of hospital stay (MD
-0.78; 95% CI -3.10 to 1.53; I2 = 56%; moderate-quality evidence; Fig 3) or length of ICU stay
(MD -3.04; 95% CI, -6.14 to 0.06; I2 = 73%; moderate-quality evidence). Four trials [6, 8, 17,
19] reported the length of mechanical ventilation. Two hundred ninety-one patients take
Fig 2. Association of vitamin D versus placebo with mortality.
https://doi.org/10.1371/journal.pone.0243768.g002
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vitamin D and 279 patients not take vitamin D. There was no association between vitamin D
and length of mechanical ventilation (MD -1.62; 95%Cl, -5.89 to 2.66; I2 = 37%).
Discussion
Principal findings
In this meta-analysis of 9 trials with a total of 2066, we did not detect a significant difference
between vitamin D and placebo as the treatment of critically ill patients for all-cause mortality.
Similarly, vitamin D supplementation does not reduce the length of ICU stay, hospital stay or
mechanical ventilation.
Comparison with other studies
Three systematic reviews and meta-analyses [11–13] have assessed the effect of vitamin D on
mortality in critically ill patients in 2017. One review [12] found that vitamin D supplements
decreased all-cause mortality at the longest follow-up in analyses of 5 trails [8–10, 17, 20] with
Fig 3. Association of vitamin D versus placebo with length of hospital stay, length of intensive care unit stay, and length of
mechanical ventilation.
https://doi.org/10.1371/journal.pone.0243768.g003
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a total of 627 patients(odd ratios 0.70, 95% confidence interval 0.50 to 0.98, p = 0.04). The
review probably reached more optimistic conclusions as to the use of odd ratios to estimate
the effect size. The other two systematic reviews [11, 13] found that vitamin D supplement was
trending to decrease all-cause mortality at the longest follow-up in critically ill, but the finding
was not statistically significant. The RRs were 0.84 (95%CI 0.66 to 1.06) and 0.77(95%CI 0.58
to 1.03), respectively.
Compared with previous meta-analyses, this study got three times the sample size to make
the results more credible. This data improved the precision concerning the treatment effects
and provided enough power to the optimum sample size in trial sequential analysis. Moreover,
this study has presented absolute as well as relative risks and rank of the quality of evidence of
main outcomes. In addition, risk of bias assessment was conducted using the new RoB 2 tool
to make the result reliable.
Limitations
The present study has the following limitations that must be taken into account. First, there
were differences across all trials in baseline characteristics (e.g., 25-hydroxyvitamin D level),
the definition of outcomes, and treatment (douse of vitamin D), leading to clinical heterogene-
ity. Secondly, due to the small number of trials, funnel plots, Egger test, and Begg’s test were
non-significant. We cannot rule out the possibility of small-study effects. Thirdly, some trials
included patients who personal supplement with vitamin D regularly. For example, in the
VIOLET trial [18], 5% of participants in the control group used vitamin D supplementation in
the past week. This made it more difficult to distinguish the effect between the treatment and
control groups.
Conclusion
Current evidence shows that vitamin D supplement was not associated with reduced all-cause
mortality in critically ill patients. Similarly, vitamin D supplementation does not reduce the
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